Table 1.
Baseline patient characteristics according to the expression level of NCALD in TCGA CN-AML patients
| Characteristics | Level | NCALD-low | NCALD-high | P-value |
|---|---|---|---|---|
| n | 20 | 55 | ||
| Sex (%) | Female | 8 (40.0) | 30 (54.5) | 0.305 |
| Male | 12 (60.0) | 25 (45.5) | ||
| Race (%) | Black | 0 (0.0) | 3 (5.5) | 0.54 |
| Others | 0 (0.0) | 1 (1.8) | ||
| Unknown | 2 (10.0) | 11 (20.0) | ||
| White | 18 (90.0) | 40 (72.7) | ||
| FAB (%) | M0 | 0 (0.0) | 3(5.5) | 0.9 |
| M1 | 8 (40.0) | 16 (29.1) | ||
| M2 | 4 (20.0) | 15 (27.3) | ||
| M4 | 4 (20.0) | 11 (20.0) | ||
| M5 | 4 (20.0) | 8 (14.5) | ||
| M7 | 0 (0.0) | 1 (1.8) | ||
| Unknown | 0 (0.0) | 1 (1.8) | ||
| Age (mean (sd)) | 51.15 (15.79) | 55.80 (17.47) | 0.3 | |
| BM_BLAST (mean (sd)) | 75.45 (15.39) | 69.02 (19.16) | 0.181 | |
| WBC (mean (sd)) × 109/L | 56.91 (53.67) | 49.00 (57.14) | 0.592 | |
| PB_BLAST (mean (sd)) | 48.00 (36.32) | 43.36 (32.46) | 0.598 | |
| Karyotype (%) | Normal | 20 (100.0) | 55 (100.0) | NA |
| Risk (%) | Intermediate | 20 (100.0) | 55 (100.0) | NA |
| Induction (%) | 7 + 3 | 8 (40.0) | 23 (41.8) | 0.852 |
| 7 + 3+3 | 6 (30.0) | 13 (23.6) | ||
| 7 + 3+3 + others | 2 (10.0) | 1 (1.8) | ||
| 7 + 3+others | 2 (10.0) | 6 (10.9) | ||
| Cytarabine | 0 (0.0) | 1 (1.8) | ||
| Decitabine | 2 (10.0) | 3 (5.5) | ||
| Decitabine + others | 0 (0.0) | 1 (1.8) | ||
| Hydrea + others | 0 (0.0) | 1 (1.8) | ||
| No treatment | 0 (0.0) | 1 (1.8) | ||
| Others | 0 (0.0) | 1 (1.8) | ||
| Revlimid | 0 (0.0) | 4 (7.3) | ||
| Transplant (%) | Auto | 3 (15.0) | 1 (1.8) | 0.34 |
| Chemotherapy | 10 (50.0) | 27 (49.1) | ||
| Haplo | 0 (0.0) | 1 (1.8) | ||
| MUD | 4 (20.0) | 12 (21.8) | ||
| No treatment | 0 (0.0) | 1 (1.8) | ||
| sib Allo | 3 (15.0) | 13 (23.6) | ||
| Before_transplant (%) | CR 1 | 7 (35.0) | 11 (20.0) | 0.876 |
| CR 2 | 2 (10.0) | 5 (9.1) | ||
| CR 3 | 0 (0.0) | 1 (1.8) | ||
| No transplant | 10 (50.0) | 27 (49.1) | ||
| No treatment | 0 (0.0) | 1 (1.8) | ||
| Others | 1 (5.0) | 7 (12.7) | ||
| Rel 1 | 0 (0.0) | 2 (3.6) | ||
| Rel 2 | 0 (0.0) | 1 (1.8) | ||
| Relapse (%) | No | 14 (70.0) | 14 (25.5) | 0.001 |
| Yes | 6 (30.0) | 41 (74.5) | ||
| DNMT3A (%) | Mutation | 7 (35.0) | 22 (40.0) | 0.846 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 13 (65.0) | 32 (58.2) | ||
| NPM1 (%) | Mutation | 13 (65.0) | 30 (54.5) | 0.705 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 7 (35.0) | 24 (43.6) | ||
| TET2 (%) | Mutation | 4 (20.0) | 5 (9.1) | 0.443 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 16 (80.0) | 49 (89.1) | ||
| FLT3 (%) | Mutation | 7 (35.0) | 23 (41.8) | 0.71 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 13 (65.0) | 31 (56.4) | ||
| IDH2 (%) | Mutation | 1 (5.0) | 9 (16.4) | 0.464 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 19 (95.0) | 45 (81.8) | ||
| IDH1 (%) | Mutation | 4 (20.0) | 5 (9.1) | 0.443 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 16 (80.0) | 49 (89.1) | ||
| RUNX1 (%) | Mutation | 0 (0.0) | 7 (12.7) | 0.228 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 20 (100.0) | 47 (85.5) | ||
| NRAS (%) | Mutation | 3 (15.0) | 3 (5.5) | 0.512 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 17 (85.0) | 51 (92.7) | ||
| WT1 (%) | Mutation | 1 (5.0) | 4 (7.3) | 1 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 19 (95.0) | 50 (90.9) | ||
| CEBPA (%) | Mutation | 4 (20.0) | 4 (7.3) | 0.326 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 16 (80.0) | 50 (90.9) | ||
| PTPN11 (%) | Mutation | 1 (5.0) | 4 (7.3) | 1 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 19 (95.0) | 50 (90.9) | ||
| KRAS (%) | Mutation | 1 (5.0) | 2 (3.6) | 1 |
| Unknown | 0 (0.0) | 1 (1.8) | ||
| WT | 19 (95.0) | 52 (94.5) |
n, number of patients; FAB, French–American–British subtypes; BM-blast, bone marrow blast; PB-blast, peripheral blood blast; WBC, white blood cell; MUD, matched unrelated donor; sib-allo HSCT, sib allogeneic stem cell transplantation; Haplo, haploidentical; CR 1, first complete remission; Rel 1, first relapse. Age, BM-blast, WBC and PB-blast statistical methods using unpaired t test, two sided. Use the Fisher’s exact test for statistical methods of categorical variables